Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe Sells 57,606 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 57,606 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.35, for a total value of $2,554,826.10. Following the transaction, the senior vice president now directly owns 4,841 shares of the company's stock, valued at $214,698.35. This trade represents a 92.25 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 3rd, Jolanda Howe sold 1,064 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total value of $51,306.08.
• On Friday, January 24th, Jolanda Howe sold 902 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $43,223.84.
• On Tuesday, January 7th, Jolanda Howe sold 750 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $32,115.00.

Mirum Pharmaceuticals Stock Down 1.8 %

NASDAQ:MIRM traded down $0.85 on Friday, hitting $47.02. The stock had a trading volume of 896,068 shares, compared to its average volume of 512,980. The business's fifty day moving average is $47.89 and its 200 day moving average is $43.70. The company has a market cap of $2.30 billion, a PE ratio of -23.28 and a beta of 1.04. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $54.23.

Remove Ads

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million during the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, equities research analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently commented on MIRM. Robert W. Baird upped their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research report on Thursday, February 27th. HC Wainwright upped their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $58.20.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at $35,000. GF Fund Management CO. LTD. bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at $42,000. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at $69,000. Finally, AlphaQuest LLC raised its stake in shares of Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after buying an additional 1,658 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.